Investors' belief in the company's poor revenue performance is likely causing its low P/S ratio. The company's bleak revenue outlook is contributing to its low P/S. These conditions form a barrier for the share price at these levels.
Shanghai Henlius Biotech's statutory profit might not fully reflect the company's underlying earning capacity due to unusual item expense. The change from loss to profit is a positive turn for the firm.
HENLIUS Stock Forum
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $INNOVENT BIO (01801.HK)$ $VENUS MEDTECH-B (02500.HK)$ $HENLIUS (02696.HK)$ $Aier Eye Hospital Group (300015.SZ)$ $Shenzhen Mindray Bio-Medical Electronics (300760.SZ)$
$MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $CSPC PHARMA (01093.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
$BEIGENE (06160.HK)$ $CSPC PHARMA (01093.HK)$ $HENLIUS (02696.HK)$ $MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
No comment yet